We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Moves -1.15%: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $57.72, moving -1.15% from the previous trading session. This change was narrower than the S&P 500's 3.25% loss on the day. Elsewhere, the Dow lost 2.42%, while the tech-heavy Nasdaq lost 0.49%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 7.64% over the past month, lagging the Medical sector's loss of 1.96% and the S&P 500's loss of 5.62% in that time.
Gilead Sciences will be looking to display strength as it nears its next earnings release. In that report, analysts expect Gilead Sciences to post earnings of $1.52 per share. This would mark a year-over-year decline of 18.72%. Our most recent consensus estimate is calling for quarterly revenue of $5.85 billion, down 5.85% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.59 per share and revenue of $24.64 billion. These results would represent year-over-year changes of -9.48% and -9.77%, respectively.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.05% lower. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 8.86. This valuation marks a discount compared to its industry's average Forward P/E of 20.16.
Meanwhile, GILD's PEG ratio is currently 0.59. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.07 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Moves -1.15%: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $57.72, moving -1.15% from the previous trading session. This change was narrower than the S&P 500's 3.25% loss on the day. Elsewhere, the Dow lost 2.42%, while the tech-heavy Nasdaq lost 0.49%.
Heading into today, shares of the HIV and hepatitis C drugmaker had lost 7.64% over the past month, lagging the Medical sector's loss of 1.96% and the S&P 500's loss of 5.62% in that time.
Gilead Sciences will be looking to display strength as it nears its next earnings release. In that report, analysts expect Gilead Sciences to post earnings of $1.52 per share. This would mark a year-over-year decline of 18.72%. Our most recent consensus estimate is calling for quarterly revenue of $5.85 billion, down 5.85% from the year-ago period.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.59 per share and revenue of $24.64 billion. These results would represent year-over-year changes of -9.48% and -9.77%, respectively.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.05% lower. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 8.86. This valuation marks a discount compared to its industry's average Forward P/E of 20.16.
Meanwhile, GILD's PEG ratio is currently 0.59. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.07 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.